^
    15h
    COBRA: Short-course Antibiotics vs Standard Course Antibiotics in Patients With Cholangitis (clinicaltrials.gov)
    P=N/A, N=440, Active, not recruiting, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Recruiting --> Active, not recruiting
    Enrollment closed
    22h
    Patient and Caregiver Perspectives on Intravesical Instillations for Urinary Symptoms (clinicaltrials.gov)
    P=N/A, N=60, Recruiting, Medstar Health Research Institute
    New trial
    1d
    Endothelial oncogenic KRAS mutation drives the dynamics of microglia and macrophages in brain arteriovenous malformation. (PubMed, JCI Insight)
    Inhibition of MG/Mϕ with long-term minocycline treatment attenuated the incidence of ICHs around bAVMs. Our study indicates that MG/Mϕ are involved in destabilization of KRAS-induced bAVM, leading to hemorrhagic conversion/ICH. Thus, modulation of MG/Mϕ may reduce ICH risk in bAVM patients.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • CCR2 (C-C Motif Chemokine Receptor 2) • CX3CR1 (C-X3-C Motif Chemokine Receptor 1)
    |
    KRAS mutation • KRAS G12
    |
    minocycline
    2d
    Cladribine Plus Homoharringtonine and Cytarabine Regimen (CHA) for de Novo Acute Myeloid Leukemia (clinicaltrials.gov)
    P2, N=65, Completed, First Affiliated Hospital of Zhejiang University | Recruiting --> Completed | N=30 --> 65 | Trial primary completion date: Aug 2025 --> Apr 2025
    Trial completion • Enrollment change • Trial primary completion date
    |
    cytarabine • cladribine • Synribo (omacetaxine mepesuccinate)
    2d
    Artemether as a modulator of EMT in colorectal cancer: enhancing radiosensitivity and reversing chemo-radiation resistance. (PubMed, BMC Gastroenterol)
    These findings provide both mechanistic insights and experimental validation for the potential application of ARE as a radiosensitizer in colorectal cancer radiotherapy.
    Journal
    |
    CTNNB1 (Catenin (cadherin-associated protein), beta 1) • CDH1 (Cadherin 1) • VIM (Vimentin) • CDH2 (Cadherin 2) • SNAI2 (Snail Family Transcriptional Repressor 2)
    3d
    Drug-Drug Interaction Between DW4421 and Amoxicillin/Clarithromycin (clinicaltrials.gov)
    P1, N=36, Not yet recruiting, Daewon Pharmaceutical Co., Ltd.
    New P1 trial
    5d
    Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=30, Recruiting, University of Washington | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • Truxima (rituximab-abbs) • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Neulasta (pegfilgrastim) • Mabtas (rituximab biosimilar) • Neupogen (filgrastim)
    6d
    Diagnosis and Treatment of Refractory Complex Skin Diseases: A Single-center, Prospective, Open-label, Non-randomized, Self-controlled Clinical Study Evaluating the Safety and Efficacy of Topical Minocycline for EGFR Inhibitor-Induced Cutaneous Adverse Reactions (ChiCTR2600116706)
    P=N/A, N=60, Not yet recruiting, Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University; Provincial People's Hospital (Guangdong Academy of
    New trial
    |
    minocycline
    6d
    Efficacy and Safety of Keverprazan-Minocycline Dual Therapy Versus Bismuth-Containing Quadruple Therapy for First-Line Eradication of Helicobacter pylori Infection: A Prospective Multicenter Randomized Controlled Trial (ChiCTR2600116736)
    P=N/A, N=340, Not yet recruiting, Northern Jiangsu People's Hospital; Northern Jiangsu People's Hospital
    New trial
    |
    minocycline
    6d
    Efficacy and Safety of Minocycline in the Treatment of Intracerebral Hemorrhage: a multicenter, randomized, open-label, blinded endpoint clinical study (ChiCTR2500114607)
    P=N/A, N=1248, Not yet recruiting, The First Hospital of Jilin University; The First Hospital of Jilin University
    New trial
    |
    minocycline
    6d
    Efficacy and safety of sequential therapy with Venetoclax, Azacitidine, and Homoharringtonine in elderly patients with de novo AML: A prospective, single-arm, multicenter, exploratory clinical trial (ChiCTR2500112019)
    P=N/A, N=40, Not yet recruiting, the First Affiliated Hospital, Zhejiang University School of Medicine; The People's Hospital Affiliated to Ningbo University
    New trial
    |
    Venclexta (venetoclax) • azacitidine • Synribo (omacetaxine mepesuccinate)
    6d
    A prospective cohort study on Helicobacter pylori infection, host-pathogen characteristics and clinical outcomes in Lanzhou, Gansu province (ChiCTR2500111516)
    P=N/A, N=4236, Not yet recruiting, Lanzhou University Second Hospital; Lanzhou University Second Hospital
    New trial